An Inbook in the American Journal of Accountable Care: Iron Supplementation in the Management of Heart Failure: Optimizing Outcomes and Resource Utilization

Program Description

Iron deficiency (ID) and iron deficiency anemia (IDA) are common comorbidities in patients with heart failure. Intravenous (IV) iron therapy has been recommended by leading heart failure guidelines over the use of oral iron supplementation in patients with ID and IDA. This article will review efficacy and safety data of IV iron, with attention to patient-reported quality of life impact. With no IV iron formulation currently preferred in the US guidelines, understanding clinical features and evidence for available IV iron products in the treatment of ID and IDA for patients with heart failure is imperative for individuals involved in formulary decision making. To encourage the use of IV iron in patients with heart failure and ID or IDA, managed care professionals can develop treatment pathways and implement formulary strategies that make IV iron available to patients. This activity will additionally examine strategies to reduce barriers to access and improve treatment approaches to reduce healthcare costs associated with ID and IDA in heart failure.

Target audience: Health-system pharmacists, managed care pharmacists

Type of activity: Application
Release date: August 29, 2022
Expiration date: August 29, 2023

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical presentation and lab values that indicate the presence of iron deficiency (ID) and iron deficiency anemia (IDA) in patients with heart failure, including its underlying pathophysiology.
• Differentiate the treatment approaches for patients with heart failure with ID/IDA under European and US guidelines, including recent clinical trial data supporting the use of intravenous (IV) iron.
• Analyze the costs of IV iron therapy and burden of illness in context with the total healthcare resource utilization required by patients with heart failure with ID/IDA.
• Optimize the managed care role in the care of patients with heart failure with ID/IDA to improve patient outcomes and support the rational allocation of healthcare resources.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-22-385-H01-P. The activity is available for CE credit through August 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jeenal Patel, PharmD

Medical Writer

Andrew Abe, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms